X

KDL Biotech Ltd Stock Analysis

Small Cap
Evaluated by 69 users | BSE: 532291 | NSE: KOPDRUGS |
Pharmaceuticals & Drugs
KDL Biotech, formerly known as Kopran Drugs was incorporated on August 12, 1986 as a private limited company. The bulk drugs division of Kopran at Khopoli was demerged and merged into KDL Biotech with effect from January 1, 1998 pursuant to order u/s 391 to 394 of the Companies Act by the...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'02Mar'03Mar'04Sep'05Mar'06Sep'07Sep'08Mar'10Mar'11Mar'12
Return on Capital Employed 6.14%5.48%1.83%-24.14%-6.75%-4.75%-14.15%-21.36%-105.3%-129.41%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 20419312410611011356.825.628.426.5
Y-o-Y Gr. Rt.--5.2%-35.9%-14.7%4.4%2.3%-49.7%-55%11%-6.8%
Adjusted EPS (Rs.) 2.051.4-1.8-17.22-13.45-5.39-8.49-6.01-23.41-7.16
Y-o-Y Gr. Rt.--31.7%-228.6%NANANANANANANA
Book Value per Share (Rs.) 35.4536.1335.156.930.29-0.1116.386.2-17.46-24.62
Adjusted Net Profit 3.42.4-3-28.9-22.6-9-20.4-14.5-56.3-17.2
Net Op. Cash Flow (Rs. Cr.) -10.634.914.26.4-1.91.7-6.32.21.66.8
Debt to Cash Flow from Ops -7.161.975.017.93-84.3332.21-10.1817.6638.368.88
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
KDL Biotech Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales -20.3%-24.9%-22.5%-6.8%
Adjusted EPS -214.9%NANANA
Book Value per Share -196-343.1-214.60
Share Price - - - -
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'02Mar'03Mar'04Sep'05Mar'06Sep'07Sep'08Mar'10Mar'11Mar'12
Return on Equity (%) 4.072.6-3.34-64.67-31.5-103.99-104.45-70.23573.8634.03
Operating Profit Margin (%) 9.788.2410.1-11.65-6.17-6.37-14.87-26.36-57.58-7.77
Net Profit Margin (%) 1.681.22-2.43-27.28-20.42-7.99-35.92-56.47-198.07-65.01
Debt to Equity 0.890.80.841.753.04-308.821.632.57-1.43-1.02
Working Capital Days 147142182127328129298211166107
Cash Conversion Cycle 626358399022-37-60-56-18
Entity Percentage Holding
Promoters 68.86%
Institutions 2.47%
Non-Institutions 28.68%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Data is not available for this company.

Data is not available for this company

KDL Biotech, formerly known as Kopran Drugs was incorporated on August 12, 1986 as a private limited company. The bulk drugs division of Kopran at Khopoli was demerged and merged into KDL Biotech with effect from January 1, 1998 pursuant to order u/s 391 to 394 of the Companies Act by the Bombay High Court. The company is a joint venture between Kopran of Parijat Enterprises, India and Synpac Kingdom Pharmaceuticals of Koo Group, Taiwan.

KDL has a biotechnology division, which manufactures

KDL Biotech, formerly known as Kopran Drugs was incorporated on August 12, 1986 as a private limited company. The bulk drugs division of Kopran at Khopoli was demerged and merged into KDL Biotech with effect from January 1, 1998 pursuant to order u/s 391 to 394 of the Companies Act by the Bombay High Court. The company is a joint venture between Kopran of Parijat Enterprises, India and Synpac Kingdom Pharmaceuticals of Koo Group, Taiwan.

KDL has a biotechnology division, which manufactures Penicillin-G acylase, the enzyme used for conversion of penicillin to 6APA. It has also successfully developed Bleomycin, an anti-cancer drug and a cytoxic antibiotic. The products under development include mitomycin, another anti-cancer drug and Vancomycin, an anti- bacterial.

KDL is one of the largest manufacturers of semi synthetic penicillin in Asia. From a 12 tonne per annum capacity in 1982-83, it expanded to a present capacity of 1200 tonnes per annum. The company's plant is approved by UK MCA, US FDA, South African MCC and several countries with strict compliance of GMP and GLP.

Milestones:

2000 - The union had declared a strike at the company's factory situated at Village Savroli, Taluka Khalapur, Khopoli, District Raigad, Maharashtra. The company's major foray into the business of biotechnology based products it was proposed to change the name of the company from Kopran Drugs to KDL Biotech for which necessary approval was been received from Registrar of Companies, Maharashtra, Mumbai. The company is a major producer of semi-synthetic penicillins (SSP) and the enzyme for converting penicillin-G to 6APA.    

2001- Crisil downgraded the company's NCDs issue to `BB+' from `BBB'.

Products:

1. Finished Dosage Forms

• Antibiotics/Antibacterial s• Anti-Malarial • Cadiovasculars • Pain Management • Anthelminthics

2. Active Pharmaceutical Ingredients

• Anti-hypertensives • Macrolides • Taste Masked • Cephalosporins

Subsidiary:

• Kopran Research Laboratories

Group companies:

• Oriental Containers • United Shippers • Shinrai Toyota • Claridge Moulded Fibre • Kopran

Alliances:

• Gujarat Themis Biosyn • Kampala Pharmaceutical Industries, Uganda

Strategic Business Units:

• Finished Dosage Forms

• Active Pharmaceutical Ingredients

• Research & Development

• Kopran Laboratories

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback